Abiopharma

🔍 Eglin Jon Stephen (Executive)

Company: DHT Holdings, Inc. (DHT)

Report Date: 2026-06-16

Detailed Transactions and Holdings:

• Acquired 6,795 shares of Common Stock (Direct)
  Date: 2026-06-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 374,622.00 | transaction_form_type: 4
• Acquired 545 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 50,545.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 6,795 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,750.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2

Footnotes:

• F1: Represents dividend equivalents, which were accrued over the term of the award and converted into additional restricted stock units in connection with the vesting of the award.
• F2: Restricted stock units were granted on January 6, 2026 and the portion reflected herein fully vested on June 16, 2026 based upon the relevant performance criteria being met. Each restricted stock unit represents a contingent right to receive, at settlement, one share of common stock or the cash value of one share of common stock. Each unit converted into a share of common stock at settlement. The remaining restricted stock units vest subject to continued employment or office, as applicable, through a specified vesting date, with 6,250 of the restricted stock units also subject to the achievement of certain market conditions prior to December 31, 2028.